Prospective Analysis of Morbi-mortality of Patients With Cancers in Active Phase of Treatment Suspected or Diagnosed of a SARS-CoV-2 Infection

CompletedOBSERVATIONAL
Enrollment

1,231

Participants

Timeline

Start Date

April 2, 2020

Primary Completion Date

June 30, 2020

Study Completion Date

June 30, 2020

Conditions
Sars-CoV2Cancer
Trial Locations (18)

14076

Centre François Baclesse, Caen

21079

Centre Georges François Leclerc, Dijon

26216

Groupement Hospitalier Porte de Provence, Montélimar

31059

Institut Universitaire du Cancer de Toulouse - IUCT Oncopole, Toulouse

34298

Institut de Cancérologie de Montpellier, Montpellier

44805

Institut de Cancérologie de l'Ouest, Saint-Herblain

51726

Institut Jean Godinot, Reims

59020

Centre Oscar Lambret, Lille

63011

Centre Jean Perrin, Clermont-Ferrand

67033

Institut de cancérologie Strasbourg Europe (ICANS), Strasbourg

69373

Centre Leon Berard, Lyon

69495

Centre Hospitalier Lyon-Sud, Pierre-Bénite

73011

Centre Hospitalier Métropole Savoie, Chambéry

74370

CH Annecy-Genevois, Metz-Tessy

76038

Centre Henri Becquerel, Rouen

Unknown

Institut Bergonié, Bordeaux

Centre Antoine Lacassagne, Nice

CH Valence, Valence

All Listed Sponsors
lead

Centre Leon Berard

OTHER

NCT04363632 - Prospective Analysis of Morbi-mortality of Patients With Cancers in Active Phase of Treatment Suspected or Diagnosed of a SARS-CoV-2 Infection | Biotech Hunter | Biotech Hunter